TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03022396

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High Dose Fluzone® (intramuscular)
Description: Licensed seasonal High dose trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® (intramuscular)
Description: Licensed seasonal trivalent inactivated influenza
Study: NCT03781661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended information
Description: The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
Study: NCT05806320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrauterine Sound Listening Group 1
Description: This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrauterine Sound Listening Group 2
Description: This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
Study: NCT03449966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal group
Description: Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
Study: NCT01207258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: 20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
Study: NCT00821652

Intervention type: DRUG
Group type: OTHER
Intervention: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod
Description: Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
Study: NCT00183157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Community Resources
Description: All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
Study: NCT02835300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CampAir
Description: CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and Referral
Description: The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
Study: NCT03142126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early ambulation with Angioseal closure device
Description: To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
Study: NCT01151410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
Study: NCT01865968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine
Description: Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine
Description: Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated HAV vaccine
Description: Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
Study: NCT01820585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 400 mg
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 800 mg
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 1200 mg
Description: tablets
Study: NCT04159623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belk Device
Description: Knee exoskeleton with electrostimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Rehabilitative treatment
Description: Use the standard rehabilitative treatment
Study: NCT01691768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% tenofovir gel
Description: Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% tenofovir gel
Description: Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm).
Study: NCT00821652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Description: Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
Study: NCT03833739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed appliance
Study: NCT01879722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets
Study: NCT03037853

Intervention type: OTHER
Intervention: Healthy volunteers
Description: MRI scanner
Study: NCT02148640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innovator infliximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biosimilar infliximab
Study: NCT01445301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2585823(CLDM 1%-BPO 3% gel)
Description: Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2585823(CLDM 1%-BPO 3% gel)
Description: Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLDM 1% gel twice daily
Description: Topical gel containing clindamycin 10 mg/1 g gel
Study: NCT02630602

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional goat cheese
Description: 60 g per day during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control cheese
Description: 60 g per day during 12 weeks
Study: NCT00723541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer aided analysis of breast lesions
Description: Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
Study: NCT02141451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB7839
Description: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB7839
Description: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB7839
Description: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB7839
Description: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
Study: NCT02810587

Intervention type: DRUG
Intervention: Topical antibiotics following injection
Description: Either receive or not receive topical antibiotics following intravitreous injection
Study: NCT00948766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 4.6 mg/24 h (5 cm^2)
Description: Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine 4.6 mg/24 h (5 cm^2)
Description: Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 9.5 mg/24 h (10 cm^2)
Description: Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 13.3 mg/24 h (15 cm^2)
Description: Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
Study: NCT04736901

Intervention type: DRUG
Intervention: Enoxaparin
Description: 0.5 mg/kg every 12 hours

Intervention type: DRUG
Intervention: Enoxaparin
Description: 40 mg/day

Intervention type: DRUG
Intervention: Rivaroxaban
Description: 10 mg once daily

Intervention type: DRUG
Intervention: Rivaroxaban
Description: 20 mg once daily

Intervention type: DRUG
Intervention: Apixaban
Description: 2.5 mg twice daily

Intervention type: DRUG
Intervention: Apixaban
Description: 5 mg twice daily
Study: NCT02769767

Intervention type: GENETIC
Intervention: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
Description: The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
Study: NCT02769767

Intervention type: GENETIC
Intervention: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
Description: The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.

Intervention type: GENETIC
Intervention: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
Description: The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.

Intervention type: GENETIC
Intervention: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
Description: The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
Study: NCT05192668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quiet time care
Description: This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected
Study: NCT02150343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM-SPIRE
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM-SPIRE
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM-SPIRE
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose every 4 weeks
Study: NCT03189745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Description: Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
Study: NCT03541031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient & Fish oil
Description: Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil & Safflower oil
Description: Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
Study: NCT03294148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo Treatment for Chronic Back Pain
Description: Subcutaneous injection of 1ml medical grade saline into the lower back.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy Treatment for Chronic Back Pain
Description: Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
Study: NCT03972085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural gliding exercises
Description: Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
Study: NCT03649217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing the iStride device
Description: The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
Study: NCT01527968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epsilon Aminocaproic Acid
Description: eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
Study: NCT03972085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy sessions
Description: Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
Study: NCT01527968

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
Study: NCT03972085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy sessions
Description: Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
Study: NCT03367390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system